Cost-effectiveness of prospective red blood cell antigen matching to prevent alloimmunization among sickle cell patients

Transfusion

Volumn 54, Issue 1, 2014, Pages 86-97

  Kacker, Seema ^a   Ness, Paul M ^a   Savage, William J ^a   Frick, Kevin D ^a   Shirey, R Sue ^a   King, Karen E ^a   Tobian, Aaron A R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROCYTE ANTIGEN;

ADULT; ALLOIMMUNIZATION; ARTICLE; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; COST EFFECTIVENESS ANALYSIS; DECISION TREE; EXCHANGE BLOOD TRANSFUSION; HEALTH CARE COST; HLA MATCHING; HUMAN; OUTCOME ASSESSMENT; POPULATION; REIMBURSEMENT; SICKLE CELL ANEMIA;

ANEMIA, HEMOLYTIC; ANEMIA, SICKLE CELL; BLOOD GROUP INCOMPATIBILITY; BLOOD GROUPING AND CROSSMATCHING; COST-BENEFIT ANALYSIS; DECISION TREES; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; HEALTH CARE COSTS; HUMANS; MARKOV CHAINS;

EID: 84891862866     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12250     Document Type: Article

References (34)

1. Centers for Disease Control and Prevention. Sickle cell disease: data and statistics. September, 2011 [cited 2012 Sep 10]. Available from: URL: http://www.cdc.gov/NCBDDD/sicklecell/data.html
2. Meny GM,. Transfusion protocols for patients with sickle cell disease: working toward consensus? Immunohematology 2012; 28: 1-2.
3. Hassell KL,. Population estimates of sickle cell disease in the U.S. Am J Prev Med 2010; 38: S512-521.
4. Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG,. The cost of health care for children and adults with sickle cell disease. Am J Hematol 2009; 84: 323-327.
5. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F,. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood 2012; 120: 528-537.
6. Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B,. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990; 322: 1617-1621. (Pubitemid 20171584)
7. Aygun B, Padmanabhan S, Paley C, Chandrasekaran V,. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002; 42: 37-43.
8. Karafin MS, Shirey RS, Ness PM, King KE,. Antigen-matched red blood cell transfusions for patients with sickle cell disease at The Johns Hopkins Hospital. Immunohematology 2012; 28: 3-6.
9. King KE, Shirey RS,. Transfusion management of patients with sickle cell disease: the continuing dilemma. Transfusion 2010; 50: 2-4.
10. Osby M, Shulman IA,. Phenotype matching of donor red blood cell units for nonalloimmunized sickle cell disease patients: a survey of 1182 North American laboratories. Arch Pathol Lab Med 2005; 129: 190-193. (Pubitemid 40204796)
11. Lerut E, Van Damme B, Noizat-Pirenne F, Emonds MP, Rouger P, Vanrenterghem Y, Pirenne J, Ansart-Pirenne H,. Duffy and Kidd blood group antigens: minor histocompatibility antigens involved in renal allograft rejection? Transfusion 2007; 47: 28-40. (Pubitemid 46006306)
12. Boyd SD, Stenard F, Lee DK, Goodnough LT, Esquivel CO, Fontaine MJ,. Alloimmunization to red blood cell antigens affects clinical outcomes in liver transplant patients. Liver Transpl 2007; 13: 1654-1661.
13. Lasalle-Williams M, Nuss R, Le T, Cole L, Hassell K, Murphy JR, Ambruso DR,. Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). Transfusion 2011; 51: 1732-1739.
14. Ambruso DR, Githens JH, Alcorn R, Dixon DJ, Brown LJ, Vaughn WM, Hays T,. Experience with donors matched for minor blood group antigens in patients with sickle cell anemia who are receiving chronic transfusion therapy. Transfusion 1987; 27: 94-98. (Pubitemid 17030045)
15. Higgins JM, Sloan SR,. Stochastic modeling of human RBC alloimmunization: evidence for a distinct population of immunologic responders. Blood 2008; 112: 2546-2553.
16. Afenyi-Annan A, Willis MS, Konrad TR, Lottenberg R,. Blood bank management of sickle cell patients at comprehensive sickle cell centers. Transfusion 2007; 47: 2089-2097. (Pubitemid 47623979)
17. National Heart, Lung, and Blood Institute. Expert panel report on the management of sickle cell disease is available for public comment until August 31. Office of the Director. 2012. [cited 2013 Mar 18]. Available from: URL: http://www.nhlbi.nih.gov/about/directorscorner/messages/2012-messages/ august-2012/expert-panel-report-on-the-management-of-sickle-cell-disease-is- available-for-public-comment-until-august-31/index.html
18. Briggs A, Sculpher M,. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13: 397-409. (Pubitemid 28140699)
19. Fasano RM, Paul W, Siegal E, Luban NL,. Transfusion protocol for patients with sickle hemoglobinopathies at Children's National Medical Center. Immunohematology 2012; 28: 13-16.
20. Vichinsky EP,. The prevention and management of alloimmunization in sickle cell disease: the benefit of extended phenotypic matching of red blood cells. Immunohematology 2012; 28: 20-23.
21. Centers for Medicare & Medicaid Services. Hospital outpatient prospective payment system: addendum A update. 2012. [cited 2012 Dec 1]. Available from: URL: http://www.cms.gov/Medicare/Medicare-Fee-for-Service- Payment/HospitalOutpatientPPS/Addendum-A-and-Addendum-B-Updates-Items/ 2012-July-Addendum-A.html
22. American Association of Blood Banks. 2013 proposed Medicare payments for hospital outpatient services. 2012 [cited 2012 Dec 1]. Available from: URL: http://www.aabb.org/programs/reimbursementinitiatives/Pages/13hoppsruleprop.aspx
23. Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK,. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Am J Hematol 2000; 64: 26-31.
24. Winkler AM, Josephson CD,. Transfusion practices for patients with sickle cell disease at major academic medical centers participating in the Atlanta Sickle Cell Consortium. Immunohematology 2012; 28: 24-26.
25. Ness PM,. To match or not to match: the question for chronically transfused patients with sickle cell anemia. Transfusion 1994; 34: 558-560.
26. Castro O, Sandler SG, Houston-Yu P, Rana S,. Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle cell disease: theoretical and practical implications. Transfusion 2002; 42: 684-690.
27. Miller ST, Kim HY, Weiner DL, Wager CG, Gallagher D, Styles LA, Dampier CD, Roseff SD,; Investigators of the Sickle Cell Disease Clinical Research Network (SCDCRN). Red blood cell alloimmunization in sickle cell disease: prevalence in 2010. Transfusion 2012; 53: 704-709.
28. Sakhalkar VS, Roberts K, Hawthorne LM, McCaskill DM, Veillon DM, Caldito GC, Cotelingam JD,. Allosensitization in patients receiving multiple blood transfusions. Ann N Y Acad Sci 2005; 1054: 495-499. (Pubitemid 43031064)
29. Vichinsky EP, Luban NL, Wright E, Olivieri N, Driscoll C, Pegelow CH, Adams RJ,. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001; 41: 1086-1092. (Pubitemid 32848083)
30. Tahhan HR, Holbrook CT, Braddy LR, Brewer LD, Christie JD,. Antigen-matched donor blood in the transfusion management of patients with sickle cell disease. Transfusion 1994; 34: 562-569. (Pubitemid 24246132)
31. Ness PM, Shirey RS, Thoman SK, Buck SA,. The differentiation of delayed serologic and delayed hemolytic transfusion reactions: incidence, long-term serologic findings, and clinical significance. Transfusion 1990; 30: 688-693. (Pubitemid 20361782)
32. Chambers JD, Neumann PJ, Buxton MJ,. Does Medicare have an implicit cost-effectiveness threshold? Med Decis Making 2010; 30: E14-27.
33. van Hulst M, de Wolf JT, Staginnus U, Ruitenberg EJ, Postma MJ,. Pharmaco-economics of blood transfusion safety: review of the available evidence. Vox Sang 2002; 83: 146-155. (Pubitemid 36807289)
34. Centers for Disease Control and Prevention. National Center for Health Statistics. VitalStats. 2013. [cited 2012 Oct 2]. Available from: URL: http://www.cdc.gov/nchs/vitalstats.htm